Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Medivir AB's current 3-Month Share Buyback Ratio was -14.72%.
Medivir AB (LTS:0GP7) 3-Month Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Medivir AB 3-Month Share Buyback Ratio Related Terms
LTS:0GP7 vs VRTX, REGN, RVMD: 3-Month Share Buyback Ratio Comparison
For the Biotechnology subindustry, Medivir AB's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB 3-Month Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's 3-Month Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Medivir AB's 3-Month Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 3-Month Share Buyback Ratio of -14.72 mean?
Medivir AB (LTS:0GP7) has a 3-Month Share Buyback Ratio of -14.72 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Medivir AB and its competitors.
Is Medivir AB's 3-Month Share Buyback Ratio too high?
Medivir AB's current 3-Month Share Buyback Ratio is -14.72. Overall, Medivir AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Medivir AB's 3-Month Share Buyback Ratio of -14.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Medivir AB and its competitors. Medivir AB's current 3-Month Share Buyback Ratio is -14.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.01, compared to a current price of kr1.90 — trading 88.2% above its estimated fair value. The current 3-Month Share Buyback Ratio is -14.72. Medivir AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current 3-Month Share Buyback Ratio is -14.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.90 is trading 88.2% above its estimated GF Value™ of kr1.01.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
3-Month Share Buyback Ratio: -14.72
GF Value™: kr1.01 vs. price of kr1.90 (88.2% above fair value)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
44GF Score
Get the complete analysis for LTS:0GP7
3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
